SEC Comment Letter for Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Apr 16, 2020
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: April 16, 2020 · CIK: 0001506251 · Accession: 0000000000-20-003314
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237638
Letter
April 16, 2020 Myron Holubiak President and Chief Executive Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 Re:Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 10, 2020 File No. 333-237638 Dear Mr. Holubiak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alec Donaldson
Show Raw Text
April 16, 2020
Myron Holubiak
President and Chief Executive Officer
Citius Pharmaceuticals, Inc.
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
Re:Citius Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed April 10, 2020
File No. 333-237638
Dear Mr. Holubiak:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alec Donaldson